Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gossamer Bio (GOSS) EBITDA Margin (2022 - 2025)

Gossamer Bio's EBITDA Margin history spans 4 years, with the latest figure at 342.63% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 2694.0% year-over-year to 342.63%; the TTM value through Dec 2025 reached 364.56%, down 31662.0%, while the annual FY2025 figure was 364.56%, 31662.0% down from the prior year.
  • EBITDA Margin reached 342.63% in Q4 2025 per GOSS's latest filing, up from 362.87% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1710.33% in Q3 2022 to a low of 390.85% in Q1 2025.
  • Average EBITDA Margin over 4 years is 496.25%, with a median of 132.11% recorded in 2024.
  • The largest YoY upside for EBITDA Margin was -1987bps in 2025 against a maximum downside of -42172bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 1612.76% in 2022, then decreased by -13bps to 1400.77% in 2023, then tumbled by -123bps to 315.69% in 2024, then dropped by -9bps to 342.63% in 2025.
  • Per Business Quant, the three most recent readings for GOSS's EBITDA Margin are 342.63% (Q4 2025), 362.87% (Q3 2025), and 370.24% (Q2 2025).